(Q42550334)

2 November 2017

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis (English)

1 reference

2 November 2017

1 reference

David L MacLeod

1

1 reference

2 November 2017

Lynn M Barker

2

1 reference

2 November 2017

Jennifer L Sutherland

3

1 reference

2 November 2017

Suzanne C Moss

4

1 reference

2 November 2017

Jesse L Gurgel

5

1 reference

2 November 2017

Thomas F Kenney

6

1 reference

2 November 2017

Jane L Burns

7

1 reference

2 November 2017

William R Baker

8

1 reference

2 November 2017

language of work or name

English

0 references

publication date

13 August 2009

1 reference

Journal of Antimicrobial Chemotherapy

2 November 2017

1 reference

2 November 2017

64

1 reference

2 November 2017

4

1 reference

2 November 2017

829-836

1 reference

Diagnosis of pathogens in exacerbations of chronic obstructive pulmonary disease.

2 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Biological costs and mechanisms of fosfomycin resistance in Escherichia coli

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Versatility of aminoglycosides and prospects for their future

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

In vitro activity of fosfomycin in combination with various antistaphylococcal substances.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Novel Fosfomycin resistance of Pseudomonas aeruginosa clinical isolates recovered in Japan in 1996.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Mutation frequencies and antibiotic resistance

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Macromolecular mechanisms of sputum inhibition of tobramycin activity

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Fosfomycin in the treatment of cystic fibrosis

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

The mechanism of action of fosfomycin (phosphonomycin)

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Treatment of respiratory infections with fosfomycin

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Fosfomycin: Laboratory Studies

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

A rat model of chronic respiratory infection with Pseudomonas aeruginosa

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

28 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2740636

Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin

16 August 2018

1 reference

12 December 2020

Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis

1 reference

12 December 2020

Activities of beta-lactams, fluoroquinolones, amikacin and fosfomycin alone and in combination against Pseudomonas aeruginosa isolated from complicated urinary tract infections

1 reference

12 December 2020

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

12 December 2020

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa

1 reference

12 December 2020

Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum

1 reference

12 December 2020

Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats

1 reference

12 December 2020

Identifiers

DOI

10.1093/JAC/DKP282

1 reference

2 November 2017

1 reference

2 November 2017

PubMed publication ID

19679597

1 reference